Completed PHASE4 INTERVENTIONAL 2-arm NCT01023217

Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir (CAESAR)

Continuation of Lamivudine Plus Adefovir Versus Switching to Entecavir Plus Adefovir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir

Sponsor: Asan Medical Center

Conditions Hepatitis B, Chronic

Interventions Adefovir Entecavir Lamivudine

Updated 6 times since 2017 Last updated: Jan 15, 2014 Started: Nov 30, 2009 Primary completion: Jul 31, 2012 Completion: Sep 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Hepatitis B, Chronic, this trial is completed. The trial is conducted by Asan Medical Center and has accumulated 6 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Asan Medical Center

Data source: Asan Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea